In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's Biotech Bust

Executive Summary

Public markets around the world are down; Germany's Neuer Markt is also out. The demise of the exchange once hailed as Europe's most promising will hit more than just Germany's listed stocks. It affects the country's private sector, too, where young companies-and their investors-are frantically seeking ways to weather the storm.
Advertisement

Related Content

Wealthy Families Play A Growing Role in European Biotech Financing
Best of the Blog, Start-Up, January 2009
Public Venture Capital for Israel's Biotech Industry
The IP Land Grab: New UK Tech Transfer Models
German Biotech: Coalescing around the Haves
OncoMethylome Sciences SA
Early M&A: The Secret of Biotech's Success
Evotec Goes Wholesale
GPC/NeoTherapeutics: Winners and Losers
Germany's Growth Story

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel